All articles by Prajapati S

Prajapati S

EC approves Sandoz’s biosimilar Ziextenzo for febrile neutropenia

Novartis unit Sandoz has received marketing authorisation from the European Commission (EC) for biosimilar Ziextenzo (pegfilgrastim).

Sun Pharmaceutical agrees to acquire Japan’s Pola Pharma

India-based drugmaker Sun Pharmaceutical Industries has signed a definitive agreement to acquire Pola Pharma, a Japan-based pharma firm involved in the research, development, manufacture, and sale of branded and generic products.

EC approves Mundipharma’s Pelmeg to treat febrile neutropenia

The Mundipharma network of independent associated companies has received European Commission (EC) approval for the use of Pelmeg (pegfilgrastim) for treatment of febrile neutropenia in adult cancer patients.

EU approves Camurus’s Buvidal injections to treat opoid dependency

Swedish research-based pharmaceutical and biotechnology company Camurus has received European Commission (EC) approval for weekly and monthly Buvidal injections to treat opioid dependency in adults and teenagers from 16 years of age.

US FDA grants ODD for OBI Pharma’s OBI-888 to treat pancreatic cancer

Taiwanese biopharma company OBI Pharma has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for OBI-888 to treat pancreatic cancer patients.

Santhera acquires exclusive sub-licence option of Vamorolone

Switzerland-based Santhera Pharmaceuticals has signed an agreement with Idorsia to acquire the option to exclusively in-license dissociative steroid vamorolone via a sub-license mode in all indications worldwide, except Japan and South Korea.

Alvotech teams with Fuji Pharma for biosimilar portfolio in Japan

Iceland-based Alvotech has signed a deal for commercialisation of its biosimilar portfolio in Japan in an exclusive partnership agreement with Fuji Pharma.